SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is trending due to heightened speculation around impending Phase 3 results for its lead AML immunotherapy, GPS, with the CEO's recent remarks on "curative outcomes" fueling strong community belief in a positive data readout and potential buyout. This has intensified discussions of a significant short squeeze as institutional accumulation is noted and the stock approaches new highs.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

ANTX is trending due to a cluster of recent positive developments including a $40 million private placement, new strategic partnerships with GSK and DNDi, and an analyst upgrade, sparking intense community debate between aggressive bulls targeting significant price appreciation and bears pointing to past trial setbacks and potential dilution.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid intense community speculation of an impending short squeeze, driven by perceived technical breakouts and widespread anticipation of strategic announcements or positive earnings from Chairman Ryan Cohen, with many noting its resilience in a volatile market.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following strong 12-month Phase 2 data for its bladder cancer candidate NDV-01 and significant new financing to advance its clinical pipeline. The community is actively discussing the promising trial results and the implications of the capital raise, with some monitoring for potential dilution.

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Calamp Corp.

Calamp Corp. is currently trending due to its Chapter 11 bankruptcy filing and plan to go private, which is expected to eliminate existing shareholder equity. Investors are actively discussing the impending delisting and the ultimate value of their holdings.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

AGH is trending due to its announced merger with drone manufacturer Powerus, a company backed by Eric Trump and Donald Trump Jr., which is transforming it from a golf course operator into a public defense-drone entity. This significant pivot is driving massive community discussion and high volume, fueled by anticipation of government contracts amid increasing demand for U.S.-made drone technology.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co. trends amid the upcoming CEO transition to Josh D'Amaro on March 18 and the successful debut of Pixar's 'Hoppers,' fueling community discussion over whether these catalysts, alongside a new stock buyback, can address ongoing concerns about content performance and valuation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is surging amid escalating tensions in the Middle East and the effective closure of the Strait of Hormuz, driving community debate on whether oil's parabolic rise is sustainable against potential strategic reserve releases by the G7.

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Solid Biosciences is trending following an oversubscribed $240 million private placement bolstering its cash runway and recent positive regulatory updates across its Duchenne, Friedreich's Ataxia, and cardiac gene therapy programs, igniting strong institutional interest and short-squeeze speculation among the community.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is surging as its new agreement with Novo Nordisk to sell branded Ozempic and Wegovy, coupled with the dismissal of a patent lawsuit, fundamentally transforms its market position in the booming GLP-1 sector. The community is actively debating a massive short squeeze and long-term upside, with many seeing the move as eliminating the main bear thesis and validating Hims' growth strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 25,745 call options on the...

<ul class="summary-bullets"><li>FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and expand brilaroxazine’s safety database.</li><li>The company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026.</li><li>The company’s current estimates project that the trial cost will be around $60 million.</li></ul>Shares of Reviva Pharmaceuticals Holdings (RVPH) plunged more than 50% on Tuesday after the FDA called for an additional Phase 3 trial of the company’s schizophrenia treatment drug, dealing a significant setback to its regulatory timeline.In written feedback, the FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and further expand brilaroxazine’s safety database before submitting a new drug application (NDA).Subject to sufficient financing, the company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026. The study is expected to mirror the design of the completed RECOVER Phase 3 trial. The FDA also provided guidance on data analysis and presentation, as well as requirements for animal pharmacokinetics, human abuse potential, and renal and hepatic impairment studies.<h2 class="st-heading-2">Cost Of The Trial</h2>According to an SEC filing, the company’s current estimates project the trial cost at around $60 million, consisting of roughly $35 million in direct trial costs and approximately $24 million in general and administrative expenses.The FDA’s recommendation follows its review of two completed randomized, double-blind, placebo-controlled studies, including one Phase 2 and one Phase 3 trial with a one-year open-label extension. Across these studies, brilaroxazine demonstrated efficacy across major schizophrenia symptom domains, including negative symptoms, in 790 participants, Reviva added.At a meeting on December 18, Reviva shareholders approved the reverse stock split charter amendment, allowing the board to implement a 1-for-2 to 1-for-20 split at its discretion before Dec. 31, 2026. Companies generally use a reverse split to meet the $1.00 minimum bid price requirement under Nasdaq listing compliance.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/RVPH">RVPH</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img style="aspect-ratio:919/97;" src="https://news.stocktwits-cdn.com/RVPH_png_6f1a479b84.webp" alt="RVPH.png" width="919" height="97"><figcaption>RVPH's Sentiment Meter and Message Volumes at 10:15 a.m. ET on Dec. 23, 2025 | Source: Stocktwits</figcaption></figure>One user opined on how the company could raise funds to cover the trial costs.<stembedurl>https://stocktwits.com/jgo1/message/639964998</stembedurl>Another user speculated about the trial timelines.<stembedurl>https://stocktwits.com/hawkeye45691/message/639962383</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spot-silver-crosses-70-an-ounce-for-the-first-time/cLep81RREuz">Spot Silver Crosses $70 An Ounce For The First Time</a> For updates and corrections, email newsroom[at]stocktwits[dot]com

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Why Did RVPH Stock Crash 50% Today?

The company announced that the FDA called for an additional Phase 3 trial of its schizophrenia treatment drug.

Equity

Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday...

Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 27,891 call options on the...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com...

Brokers Offer Predictions for RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research note issued...

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.

&nbsp;The stock market rally stalled on Tuesday, with the S&amp;P 500 Index retreating from its record closing high of 6,001.35. The weakness could be due to traders taking profit off their recent gains and shifting to the sidelines ahead of some key Main Street data on inflation and retail sales.IT, real-estate and industrial stocks served as drags, while the strength in the consumer discretionary and financial spaces offset some of the weakness.As the market pauses, here’s a compilation of stocks retailers on the Stocktwits platform are most bullish and bearish about:Most BullishNeuronetics, Inc. ($STIM)Pennsylvania-based Neuronetics, a commercial-stage med-tech company has seen its shares plunge hard following its third-quarter earnings announcement. The loss per share of $0.44 grossly missed the consensus loss estimate of $0.23, and revenue of $18.53 million also trailed the $19.14 million.The stock plunged about 40% but retail is ‘extremely” bullish on the stock.Zscaler, Inc. ($ZS)Shares of Zscaler, a San Jose, California-based cybersecurity company, rose nearly 3% on&nbsp;Tuesday following an announcement regarding its “Zero Trust Segmentation” solution.&nbsp;This solution will “provide a more secure, agile and cost-effective means to connect users, devices, and workloads across and within globally distributed branches, factories, campuses, data centers, and public clouds,” the company said.Axsome Therapeutics, Inc. ($AXSM)New York-based Axsome, which focuses on central nervous system disorders, reported a double beat for the third quarter. The stock rose over 6% following the quarterly results. The company has an FDA decision date in late January for its migraine treatment candidate.&nbsp;“We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimer’s disease agitation in the fourth quarter,” said CEO Herriot Tabuteau.Bitcoin Depot, Inc. ($BTM)Atlanta, Georgia-based Bitcoin Depot provides users with simple and efficient ways to convert cash into Bitcoin ($BTC.X).&nbsp;The company’s shares are pulling back after Monday’s 54% jump but retail held on to its bullish bias.MediciNova, Inc. ($MNOV)La Jolla, California-based MediciNova, said it was notified by Sanofi ($SNY) that the Sanofi/Novartis AG ($NVS) litigation was settled. This provides for MediciNova receiving&nbsp;a certain amount of monetary damages through this settlement. MediciNova’s stock jumped following the news, triggering positive reaction from the retail crowd.Most BearishReviva Pharmaceuticals, Holdings, Inc. ($RVPH)Reviva, a late-stage&nbsp;pharma developing therapies in the areas of central nervous system, inflammatory and cardiometabolic diseases, announced a positive update on the enrollment for the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. The stock climbed about 33% on Tuesday but retail sentiment was at a rock bottom.Pagaya Technologies Ltd. ($PGY)Israel-based Pagaya, a provider of&nbsp;financial products and services, reported a loss for the third quarter, which was much wider than expected. The stock slumped over 35%. Some among the retailers called outt the company a “fraud.Aldeyra Therapeutics, Inc. ($ALDX)Lexington, Massachusetts-based Aldeyra is a biotech focusing on therapies for immune-mediated and metabolic diseases. The shares of the company plunged on Tuesday on just about average volume.&nbsp;Retailers on the Stocktwits platform fretted over poor data for its dry eye disease product candidate.&nbsp;Quantum-Si Inc. ($QSI)Protein sequencing company Quantum-Si’s shares plunged over 22% on Tuesday after the&nbsp; Branford, Connecticut-based company reported its third-quarter results.ViaSat, Inc. ($VSAT)Shares of Carlsbad, California-based ViaSat have been ailing ever since the satellite telecommunications reported its financial results for the fiscal year 2025 second-quarter results last Thursday. This, in turn, has dented retail sentiment.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/euphoric-run-of-tesla-stock-catalyzed-by-election-result-stalled/cJ40dh1ROF">Tesla Stock’s Post-Election Rally Stalls But Analyst Talks Up His $500 Bull-Case Scenario: Retail Mood Stays Sou</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

A slew of biopharma stocks made big moves on Tuesday. 

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

RVPH
Reviva Pharmaceuticals Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RVPH News

RVPHReviva Pharmaceuticals Holdings Inc.